So, we now have multiple new classes of drugs, multiple agents that are FDA-approved for the treatment of multiple myeloma, more than 15, 16 different drugs that have become available in that period.

Regeneron, which is seeking FDA approval of linvoseltamab for adults with relapsed/refractory multiple myeloma that has progressed after at least three prior therapies, said the agency set a new ...

Pomalyst (pomalidomide) is a prescription drug that’s used to treat ... Pomalyst works to treat multiple myeloma in several ways: Pomalyst stops new cancer cells from forming by blocking the ...

In this video, Sham Mailankody, MBBS discusses the current state of the pipeline for developing multiple myeloma treatments.

John B. Amos Cancer Center at Piedmont Columbus Regional ’s midtown medical complex is the first in Georgia to offer this ...

The PDUFA action date for an FDA decision for linvoseltamab to treat adult patients with relapsed/refractory multiple myeloma ...

Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, announced today that the FDA has granted orphan drug designation (ODD) to ...

"The developers expect to create Russia's first drug for multiple myeloma based on CAR-NK therapy. It is planned that the drug using the new technology will pass all the necessary clinical trials and ...

Acceptance follows resolution of third-party fill/finish manufacturing issuesFDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, ...

The phase 2 REST trial by Frida Bugge Askeland and colleagues, reported in The Lancet Haematology, provides insight into ...

One concern with bispecific antibody therapies in community settings is managing adverse events, with emerging patterns ...